କାନାକିନୁମାବ

କାନାକିନୁମାବ
	Ribbon diagram of canakinumab (blue) bound to IL-1β (yellow) from PDB entry ଛାଞ୍ଚ:PDBe
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IL-1β
Clinical data
Trade names	Ilaris
Synonyms	ACZ885, ACZ-885
AHFS/Drugs.com	monograph
data	EU EMA: yes; US DailyMed: Canakinumab;
Pregnancy; category	AU: B3 ; US: N (Not classified yet) ;
Routes of; administration	Intravenous, subcutaneous
Legal status
Legal status	US: ℞-only ; ℞ (Prescription only);
Chemical and physical data
Formula	C6452H9958N1722O2010S42
Molar mass	145200
(verify)

କାନାକିନୁମାବ, ବେପାର ନାମ ଇଲାରିସ, ଔଷଧ ଯାହା ସାମୟିକ ଜ୍ୱର ସିଣ୍ଡ୍ରୋମ, ଗାଉଟ ଓ ଷ୍ଟିଲ୍ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୨] ସାମୟିକ ଜ୍ୱର ସିଣ୍ଡ୍ରୋମଗୁଡିକ ମଧ୍ୟରେ କ୍ରାୟୋପାଇରିନ-ସଂୟୁକ୍ତ ସାମୟିକ ସିଣ୍ଡ୍ରୋମ,(CAPS), ପାରିବାରିକ ଭୂମଧ୍ୟସାଗରୀୟ ଜ୍ୱର (FMF), ଅର୍ବୁଦ ନେକ୍ରୋସିସ୍ ଫ୍ୟାକ୍ଟର୍ ରିସେପ୍ଟର ଜଡିତ ପର୍ଯ୍ୟାୟ ସିଣ୍ଡ୍ରୋମ (TRAPS) ଏବଂ ଏଚଆଇଡି/ଏମକେଡି (HIDS / MKD) ଅନ୍ତର୍ଭୁକ୍ତ । ^[୩] ଚର୍ମ ତଳେ ଇଞ୍ଜେକ୍ସନ ଆକାରରେ ଦିଆଯାଏ । ^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନାକ ଏବଂ ଗଳାର ସଂକ୍ରମଣ, ପେଟ ଯନ୍ତ୍ରଣା, ବାନ୍ତି, ଏବଂ ଇଞ୍ଜେକ୍ସନ୍-ସାଇଟ୍ ପ୍ରତିକ୍ରିୟା ହୋଇପାରେ । ^[୨] ^[୪] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସଂକ୍ରମଣ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।^[୫] ଏହି ଔଷଧ ଖାଉଥିଲେ ଜୀବନ୍ତ ଟିକା ଗ୍ରହଣ କରିବା ଉଚିତ୍ ନୁହେଁ। ^[୫] ଏହା ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ଇଣ୍ଟରଲୁକିନ୍ -୧ ବିଟାକୁ ବନ୍ଧନ‌ଯୁକ୍ତ ହୁଏ ଏବଂ ଅବରୋଧ କରେ । ^[୩]

୨୦୦୯ରେ ଆମେରିକା ଏବଂ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ କାନାକିନୁମାବ ଅନୁମୋଦିତ ହୋଇଥିଲା । ^[୬] ^[୨] ୨୦୨୧ରେ ଯୁକ୍ତରାଜ୍ୟରେ ୧୫୦ ମିଗ୍ରାର ମୂଲ୍ୟ ୯୯୦୦ ପାଉଣ୍ଡ ଥିଲା । ^[୭] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ପ୍ରାୟ ୧୭,୫୦୦ ଡଲାର । ^[୮]

ଆଧାର

↑ Rondeau JM, Ramage P, Zurini M, Gram H (2015). "The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β". mAbs. 7 (6): 1151–60. doi:10.1080/19420862.2015.1081323. PMC 4966334. PMID 26284424.
1 2 3 "Ilaris". Archived from the original on 11 June 2020. Retrieved 29 December 2021.
1 2 3 "Ilaris". Archived from the original on 11 June 2020. Retrieved 29 December 2021.
↑ "Ilaris- canakinumab injection, powder, lyophilized, for solution Ilaris- canakinumab injection, solution". DailyMed. 14 September 2019. Archived from the original on 4 August 2020. Retrieved 16 June 2020.
1 2 "Ilaris- canakinumab injection, powder, lyophilized, for solution Ilaris- canakinumab injection, solution". DailyMed. 14 September 2019. Archived from the original on 4 August 2020. Retrieved 16 June 2020.
↑ "Canakinumab Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 July 2018. Retrieved 29 December 2021.
↑ "Ilaris Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 January 2021. Retrieved 29 December 2021.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 890. ISBN 978-0857114105.

[1] Rondeau JM, Ramage P, Zurini M, Gram H (2015). "The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β". mAbs. 7 (6): 1151–60. doi:10.1080/19420862.2015.1081323. PMC 4966334. PMID 26284424.

[EPAR2021-2] 1 2 3 "Ilaris". Archived from the original on 11 June 2020. Retrieved 29 December 2021.

[autogen1-3] 1 2 3 "Ilaris". Archived from the original on 11 June 2020. Retrieved 29 December 2021.

[PI2021-4] "Ilaris- canakinumab injection, powder, lyophilized, for solution Ilaris- canakinumab injection, solution". DailyMed. 14 September 2019. Archived from the original on 4 August 2020. Retrieved 16 June 2020.

[autogen3-5] 1 2 "Ilaris- canakinumab injection, powder, lyophilized, for solution Ilaris- canakinumab injection, solution". DailyMed. 14 September 2019. Archived from the original on 4 August 2020. Retrieved 16 June 2020.

[AHFS2021-6] "Canakinumab Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 July 2018. Retrieved 29 December 2021.

[7] "Ilaris Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 27 January 2021. Retrieved 29 December 2021.

[BNF81-8] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 890. ISBN 978-0857114105.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]